Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin;Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 5, 2005, Pages 306-316

  Carnicer, Fernando ^a   Zapater, P ^a   Gutierrez A ^b   Garcia A ^c   Ruiz, F ^a   Lopez M ^d   Pascual, S ^a   Palazon J M ^a   Perez Mateo M ^a   Such, S ^a   Garcia M F ^b   Girona, E ^b   Laveda, R ^b   Valverde, J ^c   Quilez C ^c   Martinez A ^a   De Vera, F ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c Hospital de Villajoyosa   (Spain)

^d Hospital de Alcoy   (Spain)

Author keywords

Hepatitis C; Peginterferon and ribavarin; Treatment; Unresponsive to treatment

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; COUGHING; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FEVER; FLU LIKE SYNDROME; GINGIVA BLEEDING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; IMPOTENCE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NEUTROPENIA; PERSONALITY DISORDER; PNEUMONIA; POLYMERASE CHAIN REACTION; PRURITUS; RELAPSE; RESPONSE FOLLOWING TREATMENT; SIDE EFFECT; SUSTAINED VIRAL RESPONSE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIREMIA; WEIGHT REDUCTION;

EID: 21744460188     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082005000500002     Document Type: Article

References (17)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. PEG alfa-2b plus ribavirin compared with INF alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. PEG alfa-2a plus ribavirin for patients with chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Davis GL, Esteban R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. INF alfa 2b alone o in combination withwith ribavirin for treatment of relapse of chronic hepatitis C. N. Engl J Med 1998; 339: 1493-9.
4. Diago M, Luján M, Valeros C, Tuset C, Marcaída G, García V, et al. Respuesta a largo plazo al LNF y RBV en pacientes con hepatitis cronica C sin respuesta sostenida al INF. Rev Esp Enferm Dig 2001; 93: 353-8.
5. Gaglio PJ, Zimmerman D, Choi J, Heiler L, Brown RS. Treatment with pegylated INF alpha 2b and ribavirin (Rebetol) produces significant sustantained virologie response rates in HCV infected patients who failed prior therapy. Hepatology 2003; 38 (Supl. 1): 318A.
6. Minuk GY, Reddy KR, Lee S, Heathcote J, O'Grady J, Pockcros P, et al. Enhanced virologie response to treatment with 40KD PEG 2a in patients previously unresponsive to treatment with INF 2a. Hepatology 2001; 34 (Supl. 1): 330A.
7. Portal I, Botta-Fridlun D, Bourliere M, Rotily M, Halfon P, Couzigou P, et al. Treatment with pegylated INF alfa 2B in relapserto standard INF + ribavirin in chronic hepatitis C: Efficacy and safety results from a randomized multicentricfrene study. Hepatoloy 2001; 38 (Supl. 1): 311A.
8. Adhal N, Flamm S, Malet PF, Tong M, Herrine SK, Brown R, et al. Analyses of 40 KDA PEG alfa 2a (Pegasys) in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine lus ribavirin in patients that relapsed or did not respond to rebetron thetapy: a report of two randomized, multicenter, efficacy and safety studies. Hepatology 2001; 34 (Supl. 1): 243A.
9. Shiftman ML, Di Bisceglie, Karen AM, Lindsay L, Morishima C, Wrigh EC, et al. PEG Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
10. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. INF alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
12. Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AJ, et al. Retreatment with INF plus ribavirin of chronic hepatitis C non-responders to INF monotherapy: a meta-analisys of individual patientdata. Gut 2002; 51: 864-9.
13. Bapin C, Favor-Peray, Hachemane S, Blanc F, Diaz D, Puedo P, et al. Retratment with pegylated INF alpha 2b and ribavirin in patients with chronic hepatitis C non responders to INF monoterapy or INF and ribavirin combination. A prospective randomized pilote study of two regimens: Induction versus REG. J Hepatol 2004; 40 (Supl. 1): A135.
14. Di Marco V, Almasio PL, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, et al. Combined treatment of relapse of chronic hepatitis C with high dose alfa 2b INF plus ribavirin for 6 or 12 months. J Hepatol 2000; 33: 456-62.
15. Diago M, Romero-Gómez M, Crespo J, Oliveira A, Pérez R, Bárcena R, et al. High-dose peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin (Copegus®)in patiens infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin. Hepatology 2003; 38 (Supl. 1): 740A.
16. Gross IB, Therneau TM, Johnson SM, Kwo PY, Afdhal NH, Flamm SL, et al. the renew trial: A national, multicenter study of high dose PEG alfa 2b + ribavirn for non-responders with hepatitis C. Hepatology 2003; 38 (Supl. 1): 312A.
17. White CL, Malet F, Wentworth CL, Catu VL, Alton TL, Lee WM. Interin results of a randomized trial of 1,5 μg/kg vs. 3,0 μg/kg pegylated interferon alfa 2b pegintron® (PEG) plus ribavirin (RBV) for naïve chronic hepatitis C patients and 3,0 μg/kg PEG plus RBV for non responders (NR) and relapsers (R) to previous therapy. (The target trial). Hepatology 2003; 38 (Supl. 1) 321A.